Management of Acute Coronary Syndromes Beyond the First Year: A Canadian Clinical Practice Survey

• Published in: CJC open (Online) 2020-11, Vol.2 (6), p.619-624
• Main Authors: Bui, Khai-Tuan A., Matteau, Alexis, Elbarouni, Basem, Bainey, Kevin R., Fordyce, Christopher B., Bagai, Akshay, Rose, Barry, Lutchmedial, Sohrab, Leis, Benjamin, Lavoie, Andrea, Cox, Jafna, Mansour, Samer, Potter, Brian J.
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 2589-790X; 2589-790X
• DOI: 10.1016/j.cjco.2020.08.002

Antithrombotic management following acute coronary syndromes (ACSs) has evolved significantly. However, given lingering uncertainty as to when an ACS may be considered stable, there is the possibility of practice divergence beyond the first year. An online adaptive survey describing patients with varying cardiac and extracardiac ischemic risk was developed in order to asses self-reported physician practice intentions pertaining to the antithrombotic management of ACS patients who lack a formal indication for therapeutic anticoagulation. Provincial “champions” (Prince Edward Island not represented) were identified to ensure dissemination of the survey within their jurisdictions via 3 coordinated e-mailings; the survey was made available in French and English from November 2018 through January 2019. A total of 135 practitioners responded to the survey (response rate 15%). Surveys were fully completed in all cases. Nearly all respondents (97%) were cardiologists; 76% worked at an academic center, and 54% had been in practice ≥ 10 years. Most respondents (81%-90%, depending on the scenario) preferred ticagrelor-based dual antiplatelet therapy as the initial ACS treatment. However, beyond 12 months, management decisions differed significantly according to the balance of cardiac and extracardiac risk. This study provides a first look at how the introduction of rivaroxaban 2.5 mg might be integrated into the clinical management of ACS patients beyond the first year in Canada. Whether to pursue dual antiplatelet therapy or transition early to low-dose rivaroxaban plus acetylsalicylic acid will likely be driven by patient clinical characteristics and perceived cardiac vs extra-cardiac ischemic risk. La prise en charge antithrombotique des patients ayant subi un syndrome coronarien aigu (SCA) a sensiblement évolué au fil du temps. Toutefois, compte tenu de l’incertitude qui persiste quant aux critères définissant un SCA stable, il est possible que les pratiques divergent après la première année. Nous avons mis au point un questionnaire adaptatif en ligne décrivant les cas de patients présentant divers degrés de risque d’ischémie cardiaque ou extracardiaque, afin d’évaluer les objectifs autodéclarés des médecins quant à la prise en charge antithrombotique des patients ayant subi un SCA chez qui une anticoagulothérapie n’est pas formellement indiquée. Des « champions » provinciaux (l’Île-du-Prince-Édouard n’étant pas représentée) ont été désignés pour assurer la diffu